/LPGO.ST
LPGO.ST Stock - Lipigon Pharmaceuticals AB (publ)
Healthcare|BiotechnologySTO
$0.01-4.65%
$0.00 (-4.65%) • Dec 23
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.88
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LPGO.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$0.01
STOP LOSS$0.01
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.80
52W High$0.37
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.29M | $16.41M | $390,000 | $3.18M | $4.28M |
| Gross Profit | $-26,286,000 | $-5,117,000 | $366,000 | $-36,038,000 | $-4,721,000 |
| Gross Margin | -255.5% | -31.2% | 93.8% | -1133.3% | -110.4% |
| Operating Income | $-25,576,000 | $-12,371,000 | $-37,742,000 | $-41,191,000 | $-7,824,000 |
| Net Income | $-25,264,000 | $-12,128,000 | $-37,668,000 | $-41,118,000 | $-8,068,000 |
| Net Margin | -245.6% | -73.9% | -9658.5% | -1293.0% | -188.6% |
| EPS | $-0.18 | $-0.19 | $-2.12 | $-3.35 | $-1.38 |
Company Overview
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LPGO.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.06
Q2 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | May 22, 2025 | — | $-0.06 | — | — |
Q1 2025 | Mar 28, 2025 | — | $-0.07 | — | — |
Q4 2024 | Nov 21, 2024 | — | $-0.05 | — | — |
Q3 2024 | Aug 27, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 28, 2024 | — | $-0.05 | — | — |
Q1 2024 | Feb 22, 2024 | — | $-0.09 | — | — |
Q4 2023 | Nov 23, 2023 | — | $-0.06 | — | — |
Q3 2023 | Aug 29, 2023 | — | $0.04 | — | — |
Q2 2023 | May 25, 2023 | — | $-0.34 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-0.37 | — | — |
Q4 2022 | Nov 24, 2022 | — | $-0.27 | — | — |
Q3 2022 | Aug 30, 2022 | — | $-1.07 | — | — |
Q2 2022 | May 3, 2022 | — | $-0.64 | — | — |
Q1 2022 | Feb 24, 2022 | — | $-0.73 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-1.18 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.88 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.35 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.52 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.06 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.12 | — | — |
Latest News
Loading news...
Frequently Asked Questions about LPGO.ST
What is LPGO.ST's current stock price?
Lipigon Pharmaceuticals AB (publ) (LPGO.ST) is currently trading at $0.01 per share. The stock has moved -4.65% today.
What is the analyst price target for LPGO.ST?
No analyst price targets are currently available for this stock.
What sector is Lipigon Pharmaceuticals AB (publ) in?
Lipigon Pharmaceuticals AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is LPGO.ST's market cap?
Lipigon Pharmaceuticals AB (publ) has a market capitalization of $0.00 billion, making it a small-cap company.
Does LPGO.ST pay dividends?
No, Lipigon Pharmaceuticals AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACOU.ST
AcouSort AB (publ)
$2.64
Mkt Cap: $0.1B
ATORX.ST
Alligator Bioscience AB (publ)
$0.34
Mkt Cap: $0.0B
EXPRS2.ST
ExpreS2ion Biotech Holding AB (publ)
$16.92
Mkt Cap: $0.0B
HEART.ST
Scandinavian Real Heart AB (Publ)
$14.00
Mkt Cap: $0.1B
NEWBRY.ST
Newbury Pharmaceuticals AB (publ)
$1.22
Mkt Cap: $0.0B
ONCOZ.ST
OncoZenge AB (publ)
$6.55
Mkt Cap: $0.1B
SDOS.ST
ScandiDos AB (publ)
$1.15
Mkt Cap: $0.1B
SIMRIS-B.ST
Simris Alg AB (publ)
$0.05
Mkt Cap: $0.0B
SPAGO.ST
Spago Nanomedical AB (publ)
$0.10
Mkt Cap: $0.0B
SPRINT.ST
Sprint Bioscience AB (publ)
$1.45
Mkt Cap: $0.2B
Explore stocks similar to LPGO.ST for comparison